Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

TIRHOL : A Phase 2, Multicenter, Open-Label Study of Tislelizumab (BGB-A317) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma

Male or<br/>FemaleGender Male or

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

TwoPhase Two

18+Age Over 18

Blood<br/>CancersCancer LocationBlood

Systemic therapy,Treatment | Blood / Myeloma / LymphomaHodgkin's Disease (Hodgkin's Lymphoma),Lymphoma

Trial Overview Read MoreRead more

This phase II trial is trying to understand how effective a new targeted therapy is in Hodgkin's Lymphoma patients whose cancer has got worse or not responded to previous treatment.

This trial is treating patients with Hodgkin's Lymphoma.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase 2, Multicenter, Open-Label Study of Tislelizumab (BGB-A317) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma

Commercial Sponsor

BeiGene Australia Pty Ltd

Other Non-Commercial Sponsor

Lymphoma Study Association


Patients with relapsed or refractory Classical Hodgkin Lymphoma (cHL) who have failed to achieve a response or progressed after receiving either an autologous hematopoietic stem cell transplantation (HSCT) or at least 2 prior systemic chemotherapy regimens and are not candidates for autologous or allogeneic HSCT, will receive 200 mg intravenously (IV) every 3 weeks (Q3W)

Recruiting Hospitals Read MoreRead more

Monash Health Haematology Research Unit
Miss Jeanette Gamgee
03 9594 4044

St Vincent's Hospital, Haematology Oncology Research
Ms Lisa Demosthenous
03 9231 3182

Not Recruiting Hospitals Read MoreRead more


Border Medical Oncology
Ms Kate Oates
02 6064 1499

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.